Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 2/20 | 0.43 |
| ▸ | UGCG | Q16739 | 2/20 | 0.43 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | NAAA | Q02083 | 3/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL581027 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL879887 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL1309167 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL517888 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL31490075 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL7564811 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL850609 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL4229986 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL5619569 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL5857276 | 0.98 | L3MBTL1 (0.53) | L3MBTL1TDP1TSHRHRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727915-A1 | AMIDE CONTAINING LIPIDS | Acuitas Therapeutics, Inc. (CA) | 2026-04-22 | — | — | EP | disclosed |
| EP-4561585-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION, AND PREVENTION OF ECTOPIC CALCIFICATION | Sanifit Therapeutics S.A. (ES) | 2025-06-04 | — | — | EP | disclosed |
| EP-4562019-A1 | IP5 SUBSTITUTED COMPOUNDS | Sanifit Therapeutics S.A. (ES) | 2025-06-04 | — | — | EP | disclosed |
| US-20240423914-A1 | AMIDE CONTAINING LIPIDS | Acuitas Therapeutics, Inc. (CA) | 2024-12-26 | — | — | US | disclosed |
| WO-2024259315-A1 | AMIDE CONTAINING LIPIDS | Acuitas Therapeutics, Inc. (CA) | 2024-12-19 | — | — | WO | disclosed |
| EP-4433464-A1 | NOVEL LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS | Astrazeneca AB (SE) | 2024-09-25 | — | — | EP | disclosed |
| CN-118234713-A | Novel lipids for delivery of nucleic acid segments | 阿斯利康(瑞典)有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20240109924-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | VIFOR (INTERNATIONAL) LTD. (CH) | 2024-04-04 | — | — | US | disclosed |
| WO-2024023359-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION, AND PREVENTION OF ECTOPIC CALCIFICATION | SANIFIT THERAPEUTICS, S.A. (ES) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024023360-A1 | IP5 SUBSTITUTED COMPOUNDS | SANIFIT THERAPEUTICS, S.A. (ES) | 2024-02-01 | — | — | WO | disclosed |
| US-7893304-B2 | Hydroquinone long-chain derivatives and/or phenoxy long-chain derivatives, and pharmaceuticals comprising the same | MEIJI DAIRIES CORPORATION (JP) | 2011-02-22 | — | — | US | disclosed |
| US-20090036542-A1 | Hydroquinone Long-Chain Derivative and/or Phenoxy Long-Chain Derivative and Pharmaceutical Comprising Same | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2009-02-05 | — | — | US | disclosed |
| EP-1854777-A1 | HYDROQUINONE LONG-CHAIN DERIVATIVE AND/OR PHENOXY LONG-CHAIN DERIVATIVE, AND PHARMACEUTICAL PREPARATION COMPRISING THE SAME | Meiji Dairies Corporation (JP) | 2007-11-14 | — | — | EP | disclosed |
| US-20070083058-A1 | Process for the preparation of aliphatic primary alcohols and related intermediates in such process | DSM IP ASSETS B.V. (NL) | 2007-04-12 | — | — | US | disclosed |
| US-20070083058-A1 | Process for the preparation of aliphatic primary alcohols and related intermediates in such process | DSM IP ASSETS B.V. (NL) | 2007-04-12 | — | — | US | disclosed |
| EP-1701930-A1 | PROCESS FOR THE PREPARATION OF ALIPHATIC PRIMARY ALCOHOLS AND RELATED INTERMEDIATES IN SUCH PROCESS | DSM IP Assets B.V. (NL) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005047223-A1 | PROCESS FOR THE PREPARATION OF ALIPHATIC PRIMARY ALCOHOLS AND RELATED INTERMEDIATES IN SUCH PROCESS | DSM IP ASSETS B.V. (NL) | 2005-05-26 | — | — | WO | disclosed |
| EP-0110396-B1 | IRON-TETRAPHENYLPORPHINE COMPLEX HAVING PHOSPHOCHOLINE GROUP AND OXYGEN ADSORBING AND DESORBING AGENT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1987-03-25 | — | — | EP | disclosed |
| US-4530794-A | Oxygen adsorbing, desorbing agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1985-07-23 | — | — | US | disclosed |
| EP-0110396-A2 | Iron-tetraphenylporphine complex having phosphocholine group and oxygen adsorbing and desorbing agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1984-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036542-A1 | Hydroquinone Long-Chain Derivative and/or Phenoxy Long-Chain Derivative and Pharmaceutical Comprising Same | NQO1, NDUFA10, UQCRC1 | L3MBTL1 1504/4885TDP1 2858/4885TSHR 3205/4885 |
| US-20240423914-A1 | AMIDE CONTAINING LIPIDS | PHOSPHO1, SGMS1, SGMS2 | L3MBTL1 178/4885TDP1 2503/4885TSHR 1040/4885 |
| US-20240109924-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | IPO4, TPX2, IPO9 | L3MBTL1 3016/4885TDP1 1460/4885TSHR 358/4885 |
| US-20070083058-A1 | Process for the preparation of aliphatic primary alcohols and related intermediates in such process | ADH1C, ADH1A, MSMO1 | L3MBTL1 537/4885TDP1 3817/4885TSHR 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.